Fieldpoint Private Securities’s CRISPR Therapeutics CRSP Stock Holding History

Fieldpoint Private Securities’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Hold	15	–	–	﹤0.01%	1311
2022 Q1	$1K	Hold	15	–	–	﹤0.01%	1552
2021 Q4	$1K	Hold	15	–	–	﹤0.01%	1544
2021 Q3	$2K	Sell	15 -22	-59%	-$2.76K	﹤0.01%	1452
2021 Q2	$5K	Sell	37 -4	-10%	-$486	﹤0.01%	1199
2021 Q1	$5K	Sell	41 -3,997	-99%	-$604K	﹤0.01%	1181
2020 Q4	$618K	Sell	4,038 -781	-16%	-$92.3K	0.14%	162
2020 Q3	$403K	Buy	+4,819	New	+$427K	0.12%	182

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fieldpoint Private Securities's CRSP Position: Q2 2022 in Review

Fieldpoint Private Securities held its CRISPR Therapeutics (CRSP) position steady in Q2 2022 at 15 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Fieldpoint Private Securities first reported a position in CRSP in Q3 2020 and has held it in 8 quarters since. The position peaked at $618K in Q4 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Fieldpoint Private Securities held 15 shares of CRISPR Therapeutics worth $1K as of Q2 2022.
Fieldpoint Private Securities left its CRISPR Therapeutics share count unchanged in Q2 2022.
CRISPR Therapeutics made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1311 holding.
Fieldpoint Private Securities first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 8 quarters since.
Fieldpoint Private Securities's CRISPR Therapeutics position peaked at $618K in Q4 2020.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.